1. In Vivo

A Little Light Shines On Interventional Neuroradiologists

The young and hybrid specialty of interventional neuroradiology is pushing to assume a leadership role in treatment of acute neurovascular disease. Interventional neuroradiologists are the endovascular experts who attempt to do for the brain what interventional cardiologists do for the heart. Their success has ijmplications for device companies, which are eyeing the field but hesitant to commit heavily to it because of concerns about market size and infrastructure.

Ever since UK investigators prematurely stopped enrollment in the high-profile ISAT trial in May 2002, interventional neuroradiologists (INRs) have been on a high. The first major randomized study comparing neurosurgical clipping to endovascular coil treatment of ruptured cerebral aneurysms favored coils so strongly that the study's principal investigators decided continuing it would be unfair to surgical patients. The results have already changed treatment patterns in some parts of Europe.

Nearly a year later, the American Stroke Association, at its important annual scientific meeting in February, devoted a day of...

More from Innovation

More from In Vivo

Rising Leaders 2025: J&J’s June Lanoue On Working With A Cure In Mind

 
• By Jo Shorthouse

As president of US Hematology at J&J, June Lanoue's leadership approach focuses on improving patient outcomes and organizational development. Her career path demonstrates the role of curiosity and adaptability in health care advancement.

Wide Of The Mark: ‘The Worst EU Medtech Predictions Have Not Come True’

 
• By Ashley Yeo

Jana Grieb, European regulatory and market access legal expert at McDermott Will & Emery, explains why the healthtech and pharma industries are warming to the new EU health commissioner as he faces calls to make the MDR more “user friendly.”

This Belgian Biotech’s Drug Cocktail Could Help Reverse Muscle Aging

 
• By Jo Shorthouse

While big pharma pours billions into creating new anti-aging molecules, a Belgian startup has taken a different path: combining existing safe drugs with AI precision. The early results suggest it might be onto something revolutionary.